

# General

#### Title

Stroke: percentage of ischemic stroke patients treated with IV or IA thrombolytic (t-PA) therapy or who undergo mechanical endovascular reperfusion therapy for whom a 90 day (greater than or equal to 75 days and less than or equal to 105 days) Modified Rankin Scale (mRS) is obtained via telephone or inperson.

# Source(s)

The Joint Commission. Disease-specific care certification program. Comprehensive stroke: performance measurement implementation guide. Oakbrook Terrace (IL): The Joint Commission; 2015 Mar. 278 p.

#### Measure Domain

# Primary Measure Domain

Clinical Quality Measures: Process

# Secondary Measure Domain

Does not apply to this measure

# **Brief Abstract**

# Description

This measure is used to assess the percentage of ischemic stroke patients treated with intra-venous (IV) or intra-arterial (IA) thrombolytic (t-PA) therapy or who undergo mechanical endovascular reperfusion therapy for whom a 90 day (greater than or equal to 75 days and less than or equal to 105 days) Modified Rankin Scale (mRS) is obtained via telephone or in-person.

#### Rationale

The Modified Rankin Scale (mRS) is the accepted standard for assessing recovery post-stroke. As such, it has become the most widely used clinical outcome measure for stroke clinical trials. Scores are used to measure the degree of disability or dependence in activities of daily living. Score reliability and reproducibility are improved through use of a structured interview by a trained evaluator. Interviews may

be conducted in-person or over the phone. According to guideline recommendations from the American Heart Association/American Stroke Association, standardized interviews to obtain a mRS score should be conducted for acute ischemic stroke patients treated with intravenous (IV) or intra-arterial (IA) thrombolytic (t-PA) therapy or mechanical endovascular reperfusion therapy at 3 months (90 days); however, recovery may continue well beyond 3 months for many ischemic stroke patients.

#### Evidence for Rationale

Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF, American Heart Association, American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interd[TRUNC]. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007 May;38(5):1655-711. PubMed

Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007 Mar;38(3):1091-6. PubMed

Bruno A, Akinwuntan AE, Lin C, Close B, Davis K, Baute V, Aryal T, Brooks D, Hess DC, Switzer JA, Nichols FT. Simplified modified Rankin scale questionnaire: reproducibility over the telephone and validation with quality of life. Stroke. 2011 Aug;42(8):2276-9. PubMed

Jauch EC, Saver JL, Adams HP, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H, American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Mar;44(3):870-947. PubMed

Leifer D, Bravata DM, Connors JJ, Hinchey JA, Jauch EC, Johnston SC, Latchaw R, Likosky W, Ogilvy C, Qureshi AI, Summers D, Sung GY, Williams LS, Zorowitz R, American Heart Association Special Writing Group of the Stroke Council, Atherosclerotic Peripheral Vascular Disease Working Group, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Nursing. Metrics for measuring quality of care in comprehensive stroke centers: detailed follow-up to Brain Attack Coalition comprehensive stroke center recommendations: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Mar;42(3):849-77. PubMed

Quinn TJ, Dawson J, Walters MR, Lees KR. Reliability of the modified Rankin Scale. Stroke. 2007 Nov;38(11):e144; author reply e145. PubMed

Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957 May;2(5):200-15. PubMed

Schwamm LH, Holloway RG, Amarenco P, Audebert HJ, Bakas T, Chumbler NR, Handschu R, Jauch EC, Knight WA 4th, Levine SR, Mayberg M, Meyer BC, Meyers PM, Skalabrin E, Wechsler LR, American Heart Association Stroke Council, Interdisciplinary Council on Peripheral Vascular Disease. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke. 2009 Jul;40(7):2616-34. [94 references] PubMed

The Joint Commission. Disease-specific care certification program. Comprehensive stroke: performance measurement implementation guide. Oakbrook Terrace (IL): The Joint Commission; 2015 Mar. 278 p.

Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995 Dec 14;333(24):1581-7. PubMed

Wilson JT, Hareendran A, Hendry A, Potter J, Bone I, Muir KW. Reliability of the modified Rankin Scale across multiple raters: benefits of a structured interview. Stroke. 2005 Apr;36(4):777-81. PubMed

#### Primary Health Components

Ischemic stroke; intravenous (IV) thrombolytic (t-PA) therapy; intra-arterial (IA) thrombolytic (t-PA) therapy; mechanical endovascular reperfusion therapy; Modified Rankin Scale (mRS)

#### **Denominator Description**

Ischemic stroke patients treated with intravenous (IV) or intra-arterial (IA) thrombolytic (t-PA) therapy or who undergo mechanical endovascular reperfusion therapy (see the related "Denominator Inclusions/Exclusions" field)

#### **Numerator Description**

Ischemic stroke patients for whom a 90 day (greater than or equal to 75 days and less than or equal to 105 days) Modified Rankin Scale (mRS) is obtained via telephone or in-person

# Evidence Supporting the Measure

# Type of Evidence Supporting the Criterion of Quality for the Measure

A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence

A formal consensus procedure, involving experts in relevant clinical, methodological, public health and organizational sciences

One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal

# Additional Information Supporting Need for the Measure

Unspecified

# **Extent of Measure Testing**

Unspecified

# State of Use of the Measure

#### State of Use

Current routine use

#### Current Use

not defined yet

# Application of the Measure in its Current Use

#### Measurement Setting

Hospital Inpatient

#### Professionals Involved in Delivery of Health Services

not defined yet

#### Least Aggregated Level of Services Delivery Addressed

Single Health Care Delivery or Public Health Organizations

### Statement of Acceptable Minimum Sample Size

Specified

# **Target Population Age**

Age greater than or equal to 18 years

# **Target Population Gender**

Either male or female

# National Strategy for Quality Improvement in Health Care

# National Quality Strategy Aim

Better Care

# National Quality Strategy Priority

Person- and Family-centered Care
Prevention and Treatment of Leading Causes of Mortality

# Institute of Medicine (IOM) National Health Care Quality Report Categories

#### IOM Care Need

Getting Better

#### **IOM Domain**

Effectiveness

Patient-centeredness

**Timeliness** 

# Data Collection for the Measure

# Case Finding Period

Unspecified

#### **Denominator Sampling Frame**

Patients associated with provider

## Denominator (Index) Event or Characteristic

Clinical Condition

Institutionalization

Patient/Individual (Consumer) Characteristic

Therapeutic Intervention

#### **Denominator Time Window**

not defined yet

# Denominator Inclusions/Exclusions

Inclusions

Discharges with International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Principal Diagnosis Code for ischemic stroke as defined in the appendices of the original measure documentation, AND

Patients with documented thrombolytic (intravenous [IV] or intra-arterial [IA] thrombolytic [t-PA]) therapy (ICD-9-CM Principal or Other Procedure Codes as defined in the appendices of the original measure documentation), OR

Patients with documented mechanical endovascular reperfusion therapy (ICD-9-CM Principal or Other Procedure Codes as defined in the appendices of the original measure documentation)

#### Exclusions

Patients less than 18 years of age

Patients who have a Length of Stay greater than 120 days

Patients admitted for *Elective Carotid Intervention* (as defined in the Data Elements)

Patients who expire during the hospital stay

#### Exclusions/Exceptions

not defined yet

# Numerator Inclusions/Exclusions

Inclusions

Ischemic stroke patients for whom a 90 day (greater than or equal to 75 days and less than or equal to 105 days) Modified Rankin Scale (mRS) is obtained via telephone or in-person

Exclusions

None

# Numerator Search Strategy

Institutionalization

#### **Data Source**

Administrative clinical data

Paper medical record

# Type of Health State

Does not apply to this measure

# Instruments Used and/or Associated with the Measure

- Modified Rankin Score (mRS)
- Comprehensive Stroke (CSTK) Initial Patient Population Algorithm Flowchart
- CSTK-02: Modified Rankin Score (mRS at 90 days) Flowchart

# Computation of the Measure

# Measure Specifies Disaggregation

Does not apply to this measure

# Scoring

Rate/Proportion

# Interpretation of Score

## Allowance for Patient or Population Factors

not defined yet

# Standard of Comparison

not defined yet

# **Identifying Information**

## **Original Title**

CSTK-02: modified Rankin Score (mRS at 90 Days).

#### Measure Collection Name

Advanced Certification in Disease-specific Care Measures

#### Measure Set Name

Comprehensive Stroke Standardized Performance Measures

#### Submitter

The Joint Commission - Health Care Accreditation Organization

#### Developer

The Joint Commission - Health Care Accreditation Organization

# Funding Source(s)

All external funding for measure development has been received and used in full compliance with The Joint Commission's corporate sponsorship policies, which are available upon written request to The Joint Commission.

# Composition of the Group that Developed the Measure

Unspecified

# Financial Disclosures/Other Potential Conflicts of Interest

Expert panel members have made full disclosure of relevant financial and conflict of interest information in accordance with The Joint Commission's conflict of interest policies, copies of which are available upon written request The Joint Commission.

#### Adaptation

This measure was not adapted from another source.

# Date of Most Current Version in NQMC

2015 Mar

#### Measure Maintenance

This measure is reviewed and updated by the developing organization every 6 months.

#### Date of Next Anticipated Revision

2015 Jul

#### Measure Status

This is the current release of the measure.

The measure developer reaffirmed the currency of this measure in April 2016.

# Measure Availability

Source available from The Joint Commission Web site	
For more information, contact The Joint Commission at One Renaissance Blvd., Oakbrook Terr	ace, IL
60181; Phone: 630-792-5800; Fax: 630-792-5005; Web site: www.jointcommission.org	

# **NQMC Status**

This NQMC summary was completed by ECRI Institute on May 19, 2015. The information was verified by the measure developer on June 22, 2015.

The information was reaffirmed by the measure developer on April 6, 2016.

# Copyright Statement

This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.

# Production

# Source(s)

The Joint Commission. Disease-specific care certification program. Comprehensive stroke: performance measurement implementation guide. Oakbrook Terrace (IL): The Joint Commission; 2015 Mar. 278 p.

#### Disclaimer

## **NQMC** Disclaimer

The National Quality Measures Clearinghouseâ, ¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.

All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.

Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria.

NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding measure content are directed to contact the measure developer.